Ribociclib
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
May, 2024
May 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Apr
Ribociclib
May 8, 2024, 13:20 |
Drugs
CDK4 inhibitor on the horizon - Oncology Experts
Oncology Experts shared on LinkedIn: "PF-07220060, another CDK4 inhibitor on the horizon. Reported by Pfizer…
Apr 5, 2024, 18:16 |
Insight
Timothée Olivier: NATALEE trial, adjuvant ribociclib 21 days/28 for… 3 years! Cost alert!!
Timothée Olivier, Medical Oncologist at HUG - Geneva University Hospitals, shared a post by the…
Mar 21, 2024, 10:46 |
Insight
Adding ribociclib to hormone therapy reduces the risk of breast cancer recurrence - UCLA Health
Drug regimen significantly improves invasive disease-free survival for patients with stage 2 or 3 HR-positive,…
Feb 18, 2024, 10:00 |
Blog
Paolo Tarantino: How do SONIA and NATALEE impact our use of CDK4/6-inhibitors
Paolo Tarantino, Medical Oncologist, Research Fellow at Dana-Farber Cancer Institute, shared a post on X/Twitter: “How…
Jan 29, 2024, 10:53 |
Insight
Paolo Tarantino: The highly debated results of PALOMA2 now published on JCO
Paolo Tarantino, Medical Oncologist, PhD Università degli Studi di Milano, Research Dana-Farber Cancer Institute, Harvard…
Jan 7, 2024, 15:14 |
Drugs
Paolo Tarantino: Decades of cancer research converging on new effective treatment options for our patients with HR-positive breast cancer
Paolo Tarantino, Medical Oncologist and Research Fellow at the Dana-Farber Cancer Institute, shared on LinkedIn:…
Dec 21, 2023, 16:05 |
Insight
SABCS23 Day 4 Highlights by Oncology Brothers
Oncology Brothers have recently shared their highlights from SABCS23. Below we feature the fourth day's…
Dec 17, 2023, 17:26 |
Blog
25 Posts Not To Miss From SABCS 2023
The San Antonio Breast Cancer Symposium 2023 (SABCS 2023) took place in San Antonio, Texas…
Sep 8, 2023, 18:56 |
Drugs
,
Societies
ESMO Virtual Plenary: How does adjuvant ribociclib impact the health-related quality of life of patients with HR+/HER2-. - ESMO
Quoting ESMO - European Society of Medical Oncology, on Twitter: "ESMO Virtual Plenary: How does…
Jul 14, 2023, 19:34 |
Blog
Hepatotoxicity to Ribociclib is rather common (9% g3/g4) - Dr Sarah Sammons
Hepatotoxicity to Ribociclib is rather common (9% g3/g4). I have had 4 cases now responsive…
All:
10
Posts:
1 - 10
OncoInfluencers: Dialogue with Rob Pieters, hosted by Shushan Hovsepyan
10 Most Promising Cancer Drugs Not Yet Approved: Solid Tumors - 2024 edition by OncoDaily
Elie G. Dib: Excited to share the results of the TAPUR study
OncoInfluencers: Dialogue with Fadlo R. Khuri, hosted by Gevorg Tamamyan
Cedars-Sinai is co-chairing a special AACR conference on transforming the field of Bladder Cancer on May 17-20
Facebook
RSS Feed
Twitter
Linkedin
Youtube